XRAY — DENTSPLY SIRONA Inc.

Summary of DENTSPLY SIRONA Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Q4 Revenue: $961 million, a 6.2% increase year-over-year; constant currency growth of 2.5%.
• Adjusted EBITDA Margin: 14.1%, a slight decline of 10 basis points from the previous year.
• Adjusted EPS: $0.27, up 4.9% from the prior year.
• Full Year Revenue: $3.68 billion, a decline of 3% year-over-year; constant currency decline of 4.3%.
• Full Year Adjusted EPS: $1.60, down 4.6% year-over-year.
• Operating Cash Flow: $235 million for the full year; free cash flow of $104 million.
• Net Debt-to-EBITDA Ratio: 3.0, consistent with the prior quarter.
• Dividends: $32 million paid in Q4, totaling $128 million for the year; however, the dividend has been eliminated moving forward to reallocate funds.

2. Strategic Updates and Business Highlights

• Return to Growth Action Plan: Focused on five pillars: customer-centric mindset, sustainable growth, empowering performance, scaling the organization, and financial strength.
• Leadership Changes: New hires in commercial leadership and the establishment of a transformation office to oversee the action plan.
• Segment Performance:
  • CTS: Constant currency sales down 1.9%.
  • EDS: Sales up 4% driven by growth in preventative products.
  • OIS: Sales increased 6.9%, but implant volumes declined.
  • Wellspect HealthCare: Sales increased 1.9%.
• R&D Investment: Planned double-digit increase to accelerate innovation, particularly in EDS and ortho.

3. Forward Guidance and Outlook

• 2026 Revenue Guidance: Expected in the range of $3.5 billion to $3.6 billion, reflecting a negative operational growth of 3% to 1%.
• Adjusted EPS Guidance: Projected between $1.40 and $1.50.
• Sales Momentum: Anticipated positive sequential sales growth in the second half of 2026.

4. Bad News, Challenges, or Points of Concern

• Impairment Charges: Recorded a $144 million noncash charge related to goodwill and intangible assets, primarily due to tariffs and competitive pressures.
• Sales Declines: Notable declines in CAD/CAM and implant volumes, particularly in China, with expectations for continued challenges in these areas.
• Tariff Impact: Approximately $15 million impact on gross profit in Q4; $23 million for the full year.
• Market Conditions: The overall market remains stable but not showing significant improvement, with competitive pressures noted in lower-priced products.

5. Notable Q&A Insights

• Dividend Elimination: Funds will be redirected towards debt retirement and share repurchases, with an emphasis on maintaining investment-grade credit metrics.
• Dealer Inventory Model: Transitioning to a drop-ship model, expected to impact revenue by approximately $30 million in 2026 as dealer inventories are sold through.
• Commercial Strategy: Focus on strengthening the dealer network and enhancing sales force training to improve market penetration.
• DSO Strategy: Exploring partnerships with Dental Service Organizations (DSOs) but not expecting significant movement in 2026.
• R&D Philosophy: Investments aimed at accelerating innovation, with new product launches expected to be more prevalent in 2027 and beyond.

Overall, DENTSPLY SIRONA is positioning itself for a turnaround with a clear action plan, although it faces significant challenges in terms of market conditions and competitive pressures. The focus on innovation and restructuring aims to restore growth and improve financial performance moving forward.